Recent Updates
Recently added Catalysts

cyclosporine emulsion Formulation A

Phase 1

Dry Eye Syndromes | Small molecule | Ophthalmology |AbbVie Inc.|Last Updated: Sep 7, 2015

Target and mechanism

ModalitySmall molecule

Also known as cyclosporine ophthalmic emulsion Formulation A

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Clinical trial landscape

cyclosporine emulsion Formulation A · 1 trial · 1 indication

Phase 1 1
NCT01319773Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry EyeDry Eye Syndromes
COMPLETED44 Analytics
PHASE1COMPLETED
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Dry Eye SyndromesUnlock trial analytics

Study Endpoints

Primary Endpoints

Concentration of Cyclosporine Measured in Blood at Day 1 in the Parallel-Group Phase (PGP)
Day 1

Concentration of cyclosporine measured in blood at Day 1 of the parallel-group phase (PGP). Blood samples were collected up to 3 hours post-dose and concentrations of cyclosporine were measured.

Secondary Endpoints

Number of Subjects Who Reported Ocular Symptoms During the Parallel-Group Phase (PGP)
3 Days
Number of Eyes With Ocular Symptoms Post-Dose During the Paired-Eye Phase (PEP) at Day 1
Day 1
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL

Treatment Arms

ArmTypeDescription
cyclosporine ophthalmic emulsion Formulation A (Formulation A)EXPERIMENTALParallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
cyclosporine ophthalmic emulsion Formulation B (Formulation B)EXPERIMENTALPGP: cyclosporine ophthalmic emulsion Formulation B
Formulation A and cyclosporine ophthalmic emulsion 0.05%OTHERPaired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
Formulation B and cyclosporine ophthalmic emulsion 0.05%OTHERPEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
Formulation A and Formulation BEXPERIMENTALPEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B

Interventions

NameTypeDescription
cyclosporine ophthalmic emulsion Formulation ADRUGOne drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
cyclosporine ophthalmic emulsion Formulation BDRUGOne drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%DRUGOne drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%DRUGOne drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation BDRUGOne drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Parallel-Group Phase: * Weigh at least 110 lbs * 18 to 45 years old Paired-Eye Phase: * Dry eye disease in both eyes Exclusion Criteria: Parallel-Group Phase: * Use of nicotine products, any medications, supplements or herbal products or consumption of grapefruit juice wit...

Countries:United States
Unlock Eligibility Criteria